As your sitemaster, let me be very clear about a couple of my most basic beliefs about prostate cancer and prostate cancer research. I want to do this because of all the recent media discussion about Vice President Byden’s “Moonshot” and the possible wonders of precision medicine. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: individualized, medicine, moonshot, precision, research | 16 Comments »
A recent and truly excellent review in Nature Reviews: Urology offers us a very thoughtful set of insights on the role of “expectant” and “conservative” management (i.e., active surveillance and watchful waiting) in the care of men with prostate cancer today. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, AS, care, expectant, individualized, Management, personalized, surveillance, watchful waiting | 3 Comments »
As we come, slowly, closer and closer to truly individualized forms of medical practice, in which individual patients get treated individually based not just on “what works” for most men with (say) prostate cancer that has just progressed to the metastatic stage, clinical researchers are increasingly interested in so-called “N-of-1″ clinical trials. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: individualized, medicine, N-of-one, research, trial | 2 Comments »
Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: DNA, genome, individualized, medicine, personalized, sequencing, Treatment | 10 Comments »
For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: baseline, individualized, personalized, PSA, risk, screening, testing | 10 Comments »
Dr. David Penson and colleagues at Vanderbilt University in Nashville have received a $2 million research award from the Patient-Centered Outcomes Research Institute (PCORI) to study patient-reported outcomes and compare the effectiveness of treatment of localized prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: individualized, outcome, patient-centered | Leave a comment »
There’s an interesting opinion piece on the Medscape web site today by Professor Eric Topol of the Scripps Translational Science Institute in La Jolla, California. His subject is “Consumer-driven healthcare makes docs uncomfortable.” … READ MORE …
Filed under: Uncategorized | Tagged: data, health care, individualized, Topol | 3 Comments »
Researchers at a consortium of seven major cancer centers have been awarded a $10 million, 3-year grant to continue explorations into the individualization of treatment for men with advanced and metastatic forms of prostate cancer. The grant is funded in a collaboration between Stand Up To Cancer (SU2C) and the Prostate Cancer Foundation (PCF). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: CRPC, genome, grant, individualized, reserach | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 